Latest Content

Researchers from Yale School of Medicine weigh in on what everyday clinicians can take away from their findings.

Myopia management is rarely straightforward.

The topical synthetic peptide receives orphan drug and fast track status and enters phase 2 as a first-in-class treatment for a rare degenerative corneal disease.

Yale School of Medicine researchers outline their findings and the methods of their researcher in an exclusive interview with Optometry Times.

A pilot study shows that analyzing how the cornea moves under air-puff stimulation may improve early keratoconus detection.

The university received $29.8 million through the state's Amended Fiscal Year 2026 Budget to renovate the Highway 301 building in Statesboro and create a facility to house the new program.

The product is expected to be available in stores and online at Amazon, CVS, Target and Walgreens by the end of June 2026.

The resubmission follows a successful appeal by the company with the Office of New Drugs (OND).

Host Hamza Shah, OD, MS, FAAO, is joined by Kaleb Abbott, OD, MS, to discuss eye care terminology, inspired by Abbott and Pucker's paper, "It's time to retire the terms artificial tears and rewetting drops: A call for accurate terminology and updated clinical usage in eye care."

Kevin J. Kovach, MD, and Giannie Castellanos, OD, gave their insights this season on what helps build referral trust and long-lasting comanagement relationships.

The next-generation FSYX ocular pressure adjusting pump adds wireless connectivity to transmit patient usage data to prescribing practices.

Healthy adults showed stable tear and meibum lipid composition from morning to evening in a prospective lipidomic study.

The FDA's OND found substantial evidence of effectiveness for bevacizumab-vikg in nAMD, clearing the way for a BLA resubmission in June 2026 and a decision expected within 60 days.